FDA-approved medicines exist for specific indications

Tirzepatide

Dual GIP and GLP-1 receptor agonist peptide medicine.

Editorial review: August 13, 2026

What evidence says

Evidence snapshot

This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.

Approved-indication papers below are about specific labeled product–use pairs. They do not travel to MASH, HFpEF, or a vial that is not the trial product.

Bottom line

Tirzepatide has large, labeled human trials for type 2 diabetes (including ages 10 and older), for obesity, for obesity with type 2 diabetes, for weight-loss maintenance, for obstructive sleep apnea with obesity, and for cardiovascular outcomes versus dulaglutide in type 2 diabetes. MASH and HFpEF papers exist and are not those labeled uses. An EHR comparison is not an RCT of a labeled claim.

Papers

Approved indication

PMID 34170647 — SURPASS-2

Tested: tirzepatide versus semaglutide for glycemic control in type 2 diabetes.

Does not show: an obesity claim (that is SURMOUNT), or that the comparator product is the same object as tirzepatide.

PMID 35658024 — SURMOUNT-1

Tested: tirzepatide versus placebo for body weight in adults with obesity, without diabetes.

Does not show: a diabetes-treatment claim, or a 3-year diabetes-prevention claim (see 39536238).

PMID 37385275 — SURMOUNT-2

Tested: tirzepatide versus placebo for weight in people with obesity and type 2 diabetes.

Does not show: weight effect in people without diabetes (that is SURMOUNT-1).

PMID 38078870 — SURMOUNT-4

Tested: continued tirzepatide versus withdrawal for maintenance of weight reduction in adults with obesity.

Does not show: what happens if a different product is substituted, or an unlabeled use.

PMID 38912654 — SURMOUNT-OSA

Tested: tirzepatide versus placebo for obstructive sleep apnea in adults with obesity.

Does not show: OSA treatment in people without the obesity enrollment, or a different product.

PMID 39536238 — SURMOUNT-1, 3-year

Tested: tirzepatide versus placebo over 176 weeks for weight in adults with obesity and prediabetes, and for onset of type 2 diabetes as a key secondary endpoint.

Does not show: a labeled diabetes-prevention indication. Weight in this population is the labeled object. Diabetes-prevention is not.

PMID 40353578 — SURMOUNT-5

Tested: tirzepatide versus semaglutide for weight in adults with obesity.

Does not show: that the two products are interchangeable for every use, or a non-weight claim.

PMID 41406444 — SURPASS-CVOT

Tested: tirzepatide versus dulaglutide for major adverse cardiovascular events in type 2 diabetes.

Does not show: a placebo-controlled CV claim, or CV effect in people without type 2 diabetes.

PMID 40975112 — SURPASS-PEDS

Tested: tirzepatide versus placebo for glycemic control in children and adolescents aged 10 to under 18 with type 2 diabetes inadequately controlled on metformin and/or basal insulin.

Does not show: an adult result (that is SURPASS-2), or an obesity-in-youth claim this paper did not test.

Off-label discussion

PMID 38856224 — SYNERGY-NASH

Tested: tirzepatide versus placebo for MASH with liver fibrosis.

Does not show: a labeled MASH use.

PMID 39555826 — SUMMIT

Tested: tirzepatide versus placebo for heart failure with preserved ejection fraction and obesity.

Does not show: a labeled HFpEF use.

Early human

PMID 38976257

Tested: observational EHR comparison of semaglutide versus tirzepatide for weight in adults with overweight or obesity.

Does not show: an RCT of a labeled claim. Assignment was not randomized.

What is not established

MASH and HFpEF remain unlabeled uses on this page. Diabetes-prevention on the SURMOUNT-1 3-year paper is not a labeled indication. Observational switching or comparison is not the trial object. A non-trial preparation is not SURPASS or SURMOUNT material.

Selected sources

34170647 35658024 37385275 38078870 38912654 39536238 40353578 41406444 40975112 38856224 39555826 38976257

What people discuss

Reported experiences

Blood sugar, appetite, weight, metabolic health

Reported topics are not established benefits.

Watch for

Risks and unknowns

Gastrointestinal effects, dehydration, gallbladder and pancreatic concerns, product errors

Context matters. Approval of one medicine, formulation, or use does not establish approval of products sold online or other uses. This page is educational and does not provide dosing or treatment advice.

Member discussion

Compare experiences with care.

Before posting: Describe firsthand observations and uncertainty. Do not prescribe, arrange transactions, or post private health information.

◎Verified members

Join the discussion

Verified members can contribute to compound conversations.

No approved member reports yet. Thoughtful first contributions are welcome.